Do plasma concentrations of apelin predict prognosis in patients with advanced heart failure?

Biomarkers in Medicine

Volumn 8, Issue 6, 2014, Pages 807-813

  Dalzell, Jonathan R ^a   Jackson, Colette E ^a   Chong, Kwok S ^b   McDonagh, Theresa A ^c   Gardner, Roy S ^a  

^a GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^b CROSSHOUSE HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

advanced heart failure; apelin; neurohormones; prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; APELIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE; APLN PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; BLOOD; CLINICAL TRIAL; COMPLICATION; DISEASE FREE SURVIVAL; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; PROSPECTIVE STUDY; SURVIVAL RATE;

DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84907278208     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.33     Document Type: Article

References (35)

1. Tatemoto K, Hosoya M, Habata Y et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 251, 471-476 (1998).
2. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept. 118, 119-125 (2004).
3. Katagampola SD, Maguire JJ, Matthewson SR, Davenport AP. [125I]-(Pyr1) Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Brit. J. Pharmacol. 132, 1255-1260 (2001).
4. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul. Pept.126, 233-240 (2005).
5. Hosoya M, Kawamata Y, Fukusumi S et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem. 275, 21061-21067 (2000).
6. Lee DK, Cheng R, Nguyen T et al. Characterization of apelin, the ligand for the APJ receptor. J. Neurochem. 74, 34-41 (2000).
7. Tatemoto K, Takayama K, Zou MX et al. The novel peptide apelin lowers blood pressure via a nitric oxide dependent mechanism. Regul. Pept. 99, 87-92 (2001).
8. Jia YX, Lu ZF, Zhang J et al. Apelin activates l-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 28, 2023-2029 (2007).
9. De Mota N, Reaux-Le Goazigo A, El Messari S et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc. Natl Acad. Sci. USA 28(101), 10464-10469 (2004).
10. Szokodi I, Tavi P, Foldes G et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates contractility. Circ. Res. 91, 434-400 (2002).
11. Farkasfalvi K, Stagg MA, Coppen SR et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem. Biophys. Res. Comm. 357, 889-895 (2007).
12. Jia YX, Pan CS, Zhang J et al. Apelin protects myocardial injury induced by isoproterenol in rats. Regul. Pept. 133, 147-154 (2006).
13. Berry MF, Pirolli TJ, Jayasankar V et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 110, 187-193 (2004).
14. Ashley EA, Powers J, Chen M et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc. Res. 65, 73-82 (2005).
15. Japp AG, Cruden NL, Amer DA et al. Vascular effects of apelin in vivo in man. J. Am. Coll. Cardiol. 52, 908-913 (2008).
16. Japp AG, Cruden NL, Barnes G et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 121, 1818-1827 (2010).
17. Barnes GD, Alam S, Carter G et al. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ. Heart Fail. 6, 482-491 (2013).
18. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur. J. Heart Fail. 8, 355-360 (2006).
19. Chen MM, Ashley EA, Deng DX et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108, 1432-1439 (2003).
20. Francia P, Salvati A, Balla C et al. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur. J. Heart Fail. 9, 306-309 (2007).
21. Goetze JP, Rehfeld JF, Carlsen J et al. Apelin: a new plasma marker of cardiopulmonary disease. Regul. Pept. 133, 134-138 (2006).
22. Földes G, Horkay F, Szokodi I et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem. Biophys. Res. Commun. 308, 480-485 (2003).
23. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95, 2660-2667 (1997).
24. Van Kimmenade RR, Januzzi JL Jr. Emerging biomarkers in heart failure. Clin. Chem. 58, 127-138 (2012).
25. van Kimmenade RR, Januzzi JL Jr, Ellinor PT et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 48, 1217-1224 (2006).
26. Mullens W, Bartunek J, Wilson Tang WH et al. Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm 5, 52-59 (2008).
27. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of the angiotensin II-angiotensin type I receptor system. J. Mol. Cell. Cardiol. 798-806 (2006).
28. Ishida J, Hashimoto T, Hashimoto Y et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J. Biol. Chem. 279, 26274-26279 (2004).
29. Koguchi W, Kobayashi N, Takeshima H, Ishikawa M, Sugiyama F, Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ. J. 76, 137-144 (2012).
30. Jia YX, Pan CS, Zhang J et al. Apelin protects myocardial injury induced by isoproterenol in rats. Regul. Pept. 133, 147-154 (2006).
31. Fukushima H, Kobayashi N, Takeshima H, Koguchi W, Ishimitsu T. Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure. J. Cardiovasc. Pharmacol. 55, 83-88 (2010).
32. Miettinen KH, Magga J, Vuolteenaho O et al. Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul. Pept. 140, 178-184 (2007).
33. Dalzell JR, Jackson CE. Novel neurohormonal insights with therapeutic potential in chronic heart failure. Future Cardiol. 6, 361-372 (2010).
34. Fisher C, Berry C, Blue L, Morton JJ, McMurray J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 89, 879-881 (2003).
35. Teerlink JR, Cotter G, Davison BA et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381, 29-39 (2013).